OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

Pharmaceutical

OnDosis

Martin Olovsson

Stina Wigren

Stefan Kristo

Stéphane Baronnet

Joshua Carney

The Leadership Team at OnDosis is responsible for guiding the company’s strategic direction and ensuring alignment with its mission to revolutionize individualized dosing in disease management. This team, comprising the CEO and Co-Founder, Chief Digital Officer (CDO), and Chief Operating Officer (COO), oversees major operational and digital initiatives, fosters strategic partnerships, and drives innovation in product development to support patient adherence and improve healthcare outcomes.

Leadership Team

Engineering Team

Development

Leadership Team

About

Team members

Other teams at OnDosis

Engineering Team

Development